New combo therapy for advanced lung cancer shows safety data in Real-World study

NCT ID NCT05826366

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked 296 patients with advanced or recurrent non-small cell lung cancer who received a combination of IMJUDO, IMFINZI, and platinum-based chemotherapy. The goal was to see how safe the treatment is in everyday medical practice. Researchers recorded any side effects that occurred during treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Research Site

Aichi, Japan
Research Site

Chiba, Japan
Research Site

Fukuoka, Japan
Research Site

Fukushima, Japan
Research Site

Gifu, Japan
Research Site

Gunma, Japan
Research Site

Hiroshima, Japan
Research Site

Hokkaido, Japan
Research Site

Hyōgo, Japan
Research Site

Ibaraki, Japan
Research Site

Ishikawa, Japan
Research Site

Kagawa, Japan
Research Site

Kanagawa, Japan
Research Site

Kyoto, Japan
Research Site

Mie, Japan
Research Site

Miyagi, Japan
Research Site

Miyazaki, Japan
Research Site

Nara, Japan
Research Site

Okayama, Japan
Research Site

Osaka, Japan
Research Site

Shizuoka, Japan
Research Site

Tochigi, Japan
Research Site

Tokyo, Japan
Research Site

Tottori, Japan
Research Site

Toyama, Japan
Research Site

Wakayama, Japan
Research Site

Yamagata, Japan
Research Site

Yamaguchi, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.